Product Description: L-745870 is a potent, selective, brain-penetrant and orally active dopamine D4 receptor antagonist with a Ki of 0.43 nM. L-745870 shows weaker affinity for D2 (Ki of 960 nM) and D3 (Ki of 2300 nM) receptors, and exhibits moderate affinity for 5-HT2 receptors, sigma sites and α-adrenoceptors[1][2][3].
Applications: Neuroscience-Neuromodulation
Formula: C18H19ClN4
Citations: Br J Cancer. 2024 Aug 22./Research Square Preprint. 2023 Oct 3./Psychopharmacology. 2022 Sep 15.
References: [1]Bristow LJ, et al. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci. 1997 Jun;18(6):186-8./[2]Patel S, et al. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Nov;283(2):636-47./[3]Kulagowski JJ, et al. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem. 1996 May 10;39(10):1941-2.
CAS Number: 158985-00-3
Molecular Weight: 326.82
Compound Purity: 99.92
Research Area: Neurological Disease
Solubility: DMSO : 25 mg/mL (ultrasonic)
Target: Dopamine Receptor
English
Deutsch
